In order to assess the response of AML cells to targeted pathway inhibition, the two different FLT3‐ITD‐mutated AML cell lines MOLM‐14 and MV4‐11, with reported GLI expression (Lim et al. The gene discussed is GLI1; the disease is acute myeloid leukemia.